Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial

Fenske SJ, Liu J, Chen H, Diniz MA, Stephens RL, Cornea E, Gilmore JH, Gao W. Sex differences in brain-behavior relationships in the first 2[...]

Silva TF, Hutchins E, Zhao W, Ciani Y, Kim M, Ko E, Mariscal J, Qiu Z, Bedier F, Kittel A, Zhou B, Wang Y, Hall[...]

Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel[...]